查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1869587

坏死性筋膜炎市场规模、份额和趋势分析报告：按类型、治疗方法、分销管道、地区和细分市场预测，2025-2033年

Necrotizing Fasciitis Market Size, Share & Trends Analysis Report By Type, By Treatment, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

坏死性筋膜炎市场摘要

2024年全球坏死性筋膜炎市场规模估计为10.2724亿美元，预计2033年将达到20.9781亿美元。

预计2025年至2033年间，该市场将以8.3%的复合年增长率成长。推动市场成长的几个关键因素包括：人们对该疾病的严重和快速进展的认识不断提高，从而增加了对有效治疗方法的需求。

医疗技术的进步以及创新抗生素和外科手术的广泛应用改善了患者的治疗效果，进一步推动了市场扩张。坏死性筋膜炎（NF）是严重的皮肤和软组织感染疾病，沿着血流受限的筋膜间隙扩散。在早期，浅表组织通常不受影响，导致诊断和治疗延误。随着病情进展，可涉及筋膜、筋膜周围间隙、周围皮肤、软组织和肌肉。在美国，此病的年发生率约为每10万人0.4例，部分地区的发生率甚至低至每10万人1例。

此外，糖尿病、肥胖和免疫力缺乏功能低下等风险因素的日益普遍也导致了病例数的增加。根据国际糖尿病联盟预测，到2024年，糖尿病将导致340万人死亡，相当于每9秒钟就有一人死于糖尿病。此外，全球有5.89亿成年人（20-79岁）患有糖尿病。糖尿病患者人数的不断增长显着增加了坏死性筋膜炎的风险，从而推动了对专科护理的需求。此外，医疗机构对早期诊断和治疗的日益重视，以及医疗费用支出，都促进了该市场的稳定成长。

目录

第一章调查方法和范围

第二章执行摘要

第三章 坏死性筋膜炎市场变数、趋势与范围

  • 市场体系展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 商业环境分析
    • 产业分析—波特五力分析
    • PESTLE分析
    • 管道分析

第四章 坏死性筋膜炎市场：按类型分類的业务分析

  • 按类型分類的市场份额，2024 年和 2033 年
  • 类型细分仪表板
  • 市场规模、预测与趋势分析（按类型，2021-2033 年）
  • I 型（多微生物）
  • Ⅱ型（单菌型）
  • 第三型（气性坏疽/梭菌性肌肉坏死）

5. 坏死性筋膜炎市场：依疗法分類的业务分析

  • 按疗法分類的市场份额，2024 年和 2033 年
  • 治疗细分仪表板
  • 按疗法分類的市场规模、预测和趋势分析，2021-2033年
  • 经验性广效抗生素
  • 可附加MRSA（耐甲氧西林金黄色葡萄球菌）感染防治方案
  • 辅助抗毒素用于治疗侵袭性A类链球菌感染。
  • 针对特定病原体的抗菌治疗
  • 用于治疗坏死性真菌感染疾病的抗真菌药物
  • 免疫疗法

6. 坏死性筋膜炎市场：按通路分類的业务分析

  • 按分销管道分類的市场份额，2024 年和 2033 年
  • 分销通路细分仪表板
  • 按分销管道分類的市场规模、预测和趋势分析，2021-2033年
  • 医院药房
  • 零售药房
  • 网路药房

第七章 坏死性筋膜炎市场：区域估算与趋势分析

  • 2024 年及 2033 年区域市占率分析
  • 区域市场概览
  • 市场规模及预测趋势分析（2021-2033）：
  • 北美洲
    • 按国家/地区划分，2021-2033 年
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争情势

  • 参与者概览
  • 企业市场分析
  • 公司分类
  • 策略规划
  • 公司简介
    • Pfizer Inc.
    • Merck &Co., Inc.（MSD）
    • Gilead Sciences
    • Astellas Pharma
    • Basilea Pharmaceutica
    • CSL Behring
    • Takeda
    • Grifols
    • Octapharma
    • Hikma Pharmaceuticals
Product Code: GVR-4-68040-771-4

Necrotizing Fasciitis Market Summary

The global necrotizing fasciitis market size was estimated at USD 1,027.24 million in 2024 and is projected to reach USD 2,097.81 million by 2033, growing at a CAGR of 8.3% from 2025 to 2033. The market is experiencing growth due to several key factors. Increasing awareness about the severity and rapid progression of the disease has led to a higher demand for effective treatments.

Advances in medical technology and the availability of innovative antibiotics and surgical interventions improve patient outcomes, further driving market expansion. Necrotizing Fasciitis (NF) is a serious skin and soft tissue infection that spreads along fascial planes with limited blood supply. It often leaves overlying tissues initially unaffected and delays diagnosis and treatment. As it progresses, it can involve fascia, peri-fascial planes, surrounding skin, soft tissue, and muscle. The condition affects around 0.4 per 100,000 people in the U.S. annually, with some areas reporting up to 1 per 100,000.

In addition,the rising prevalence of risk factors such as diabetes, obesity, and immunocompromised conditions is contributing to a greater number of cases. According to the International Diabetes Federation, diabetes was responsible for 3.4 million deaths in 2024, equivalent to one death every nine seconds, and 589 million adults (aged 20-79 years) are living with the condition worldwide. This rising diabetic population significantly increases the susceptibility to Necrotizing Fasciitis, fueling the demand for specialized care. Moreover, the growing focus of healthcare providers on early diagnosis and treatment, along with increased healthcare spending, is supporting the market's steady growth.

Global Necrotizing Fasciitis Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global necrotizing fasciitis market report based on type, treatment, distribution channel, and region:

  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Type I (Polymicrobial)
  • Type II (Monomicrobial)
  • Type III (Gas gangrene / clostridial myonecrosis)
  • Treatment Outlook (Revenue, USD Million, 2021 - 2033)
  • Empiric broad-spectrum antibacterials
  • MRSA-coverage add-ons
  • Antitoxin adjunct for invasive GAS
  • Pathogen-targeted antibacterial regimens
  • Antifungals for necrotizing fungal infections
  • Immunotherapies
  • Distribution ChannelOutlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • MEA
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Treatment
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Necrotizing Fasciitis Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis

Chapter 4. Necrotizing Fasciitis Market: Type Business Analysis

  • 4.1. Type Market Share, 2024 & 2033
  • 4.2. Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 - 2033 (USD Million)
  • 4.4. Type I (Polymicrobial)
    • 4.4.1. Type I (Polymicrobial) market estimates & forecasts, 2021 - 2033 (USD Million)
  • 4.5. Type II (Monomicrobial)
    • 4.5.1. Type II (Monomicrobial) market estimates & forecasts, 2021 - 2033 (USD Million)
  • 4.6. Type III (Gas gangrene / clostridial myonecrosis)
    • 4.6.1. Type III (Gas gangrene / clostridial myonecrosis) market estimates & forecasts, 2021 - 2033 (USD Million)

Chapter 5. Necrotizing Fasciitis Market: Treatment Business Analysis

  • 5.1. Treatment Market Share, 2024 & 2033
  • 5.2. Treatment Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2021 to 2033 (USD Million)
  • 5.4. Empiric broad-spectrum antibacterials
    • 5.4.1. Empiric broad-spectrum antibacterials market estimates & forecasts, 2021 - 2033 (USD Million)
  • 5.5. MRSA-coverage add-ons
    • 5.5.1. MRSA-coverage add-ons market estimates & forecasts, 2021 - 2033 (USD Million)
  • 5.6. Antitoxin adjunct for invasive GAS
    • 5.6.1. Antitoxin adjunct for invasive GAS market estimates & forecasts, 2021 - 2033 (USD Million)
  • 5.7. Pathogen-targeted antibacterial regimens
    • 5.7.1. Pathogen-targeted antibacterial regimens market estimates & forecasts, 2021 - 2033 (USD Million)
  • 5.8. Antifungals for necrotizing fungal infections
    • 5.8.1. Antifungals for necrotizing fungal infections market estimates & forecasts, 2021 - 2033 (USD Million)
  • 5.9. Immunotherapies
    • 5.9.1. Immunotherapies market estimates & forecasts, 2021 - 2033 (USD Million)

Chapter 6. Necrotizing Fasciitis Market: Distribution Channel Business Analysis

  • 6.1. Distribution Channel Market Share, 2024 & 2033
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
  • 6.4. Hospital Pharmacies
    • 6.4.1. Hospital pharmacies market estimates & forecasts, 2021 - 2033 (USD Million)
  • 6.5. Retail Pharmacies
    • 6.5.1. Retail pharmacies market estimates & forecasts, 2021 - 2033 (USD Million)
  • 6.6. Online pharmacies
    • 6.6.1. Online pharmacies market estimates & forecasts, 2021 - 2033 (USD Million)

Chapter 7. Necrotizing Fasciitis Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2033
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 7.4. North America
    • 7.4.1. North America necrotizing fasciitis market estimates & forecasts, by country, 2021 - 2033 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Type disease prevalence
      • 7.4.2.3. Regulatory framework
      • 7.4.2.4. Reimbursement framework
      • 7.4.2.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Type disease prevalence
      • 7.4.3.3. Regulatory framework
      • 7.4.3.4. Reimbursement framework
      • 7.4.3.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Type disease prevalence
      • 7.4.4.3. Regulatory framework
      • 7.4.4.4. Reimbursement framework
      • 7.4.4.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe necrotizing fasciitis market estimates & forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Type disease prevalence
      • 7.5.2.3. Regulatory framework
      • 7.5.2.4. Reimbursement framework
      • 7.5.2.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Type disease prevalence
      • 7.5.3.3. Regulatory framework
      • 7.5.3.4. Reimbursement framework
      • 7.5.3.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Type disease prevalence
      • 7.5.4.3. Regulatory framework
      • 7.5.4.4. Reimbursement framework
      • 7.5.4.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Type disease prevalence
      • 7.5.5.3. Regulatory framework
      • 7.5.5.4. Reimbursement framework
      • 7.5.5.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Type disease prevalence
      • 7.5.6.3. Regulatory framework
      • 7.5.6.4. Reimbursement framework
      • 7.5.6.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key country dynamics
      • 7.5.7.2. Type disease prevalence
      • 7.5.7.3. Regulatory framework
      • 7.5.7.4. Reimbursement framework
      • 7.5.7.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key country dynamics
      • 7.5.8.2. Type disease prevalence
      • 7.5.8.3. Regulatory framework
      • 7.5.8.4. Reimbursement framework
      • 7.5.8.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key country dynamics
      • 7.5.9.2. Type disease prevalence
      • 7.5.9.3. Regulatory framework
      • 7.5.9.4. Reimbursement framework
      • 7.5.9.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific necrotizing fasciitis market estimates & forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. China
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Type disease prevalence
      • 7.6.2.3. Regulatory framework
      • 7.6.2.4. Reimbursement framework
      • 7.6.2.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. Japan
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Type disease prevalence
      • 7.6.3.3. Regulatory framework
      • 7.6.3.4. Reimbursement framework
      • 7.6.3.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Type disease prevalence
      • 7.6.4.3. Regulatory framework
      • 7.6.4.4. Reimbursement framework
      • 7.6.4.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Type disease prevalence
      • 7.6.5.3. Regulatory framework
      • 7.6.5.4. Reimbursement framework
      • 7.6.5.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Type disease prevalence
      • 7.6.6.3. Regulatory framework
      • 7.6.6.4. Reimbursement framework
      • 7.6.6.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Type disease prevalence
      • 7.6.7.3. Regulatory framework
      • 7.6.7.4. Reimbursement framework
      • 7.6.7.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America necrotizing fasciitis market estimates & forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Type disease prevalence
      • 7.7.2.3. Regulatory framework
      • 7.7.2.4. Reimbursement framework
      • 7.7.2.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Type disease prevalence
      • 7.7.3.3. Regulatory framework
      • 7.7.3.4. Reimbursement framework
      • 7.7.3.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
  • 7.8. Middle East and Africa
    • 7.8.1. Middle East and Africa necrotizing fasciitis market estimates & forecasts, 2021 - 2033 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Type disease prevalence
      • 7.8.2.3. Regulatory framework
      • 7.8.2.4. Reimbursement framework
      • 7.8.2.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Type disease prevalence
      • 7.8.3.3. Regulatory framework
      • 7.8.3.4. Reimbursement framework
      • 7.8.3.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key country dynamics
      • 7.8.4.2. Type disease prevalence
      • 7.8.4.3. Regulatory framework
      • 7.8.4.4. Reimbursement framework
      • 7.8.4.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key country dynamics
      • 7.8.5.2. Type disease prevalence
      • 7.8.5.3. Regulatory framework
      • 7.8.5.4. Reimbursement framework
      • 7.8.5.5. Market estimates & forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Pfizer Inc.
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Merck & Co., Inc. (MSD)
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Gilead Sciences
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Astellas Pharma
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Basilea Pharmaceutica
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. CSL Behring
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Takeda
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Grifols
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Octapharma
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Hikma Pharmaceuticals
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List Of Secondary Sources
  • Table 2 List Of Abbreviations
  • Table 3 Global Necrotizing Fasciitis Market, By Region, 2021 - 2033 (USD Million)
  • Table 4 Global Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 5 Global Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 6 Global Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 7 North America Necrotizing Fasciitis Market, By Country, 2021 - 2033 (USD Million)
  • Table 8 North America Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 9 North America Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 10 North America Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 11 U.S. Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 12 U.S. Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 13 U.S. Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 14 Canada Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 15 Canada Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 16 Canada Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 17 Mexico Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 18 Mexico Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 19 Mexico Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 20 Europe Necrotizing Fasciitis Market, By Country, 2021 - 2033 (USD Million)
  • Table 21 Europe Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 22 Europe Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 23 Europe Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 24 UK Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 25 UK Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 26 UK Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 27 Germany Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 28 Germany Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 29 Germany Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 30 France Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 31 France Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 32 France Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 33 Italy Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 34 Italy Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 35 Italy Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 36 Spain Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 37 Spain Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 38 Spain Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 39 Denmark Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 40 Denmark Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 41 Denmark Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 42 Sweden Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 43 Sweden Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 44 Sweden Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 45 Norway Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 46 Norway Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 47 Norway Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 48 Asia Pacific Necrotizing Fasciitis Market, By Country, 2021 - 2033 (USD Million)
  • Table 49 Asia Pacific Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 50 Asia Pacific Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 51 Asia Pacific Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 52 Japan Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 53 Japan Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 54 Japan Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 55 China Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 56 China Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 57 China Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 58 India Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 59 India Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 60 India Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 61 Australia Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 62 Australia Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 63 Australia Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 64 South Korea Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 65 South Korea Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 66 South Korea Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 67 Thailand Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 68 Thailand Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 69 Thailand Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 70 Latin America Necrotizing Fasciitis Market, By Country, 2021 - 2033 (USD Million)
  • Table 71 Latin America Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 72 Latin America Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 73 Latin America Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 74 Brazil Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 75 Brazil Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 76 Brazil Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 77 Argentina Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 78 Argentina Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 79 Argentina Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 80 Middle East & Africa Necrotizing Fasciitis Market, By Country, 2021 - 2033 (USD Million)
  • Table 81 Middle East & Africa Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 82 Middle East & Africa Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 83 Middle East & Africa Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 84 South Africa Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 85 South Africa Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 86 South Africa Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 87 Saudi Arabia Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 88 Saudi Arabia Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 89 Saudi Arabia Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 90 UAE Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 91 UAE Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 92 UAE Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 93 Kuwait Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 94 Kuwait Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 95 Kuwait Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Necrotizing fasciitis market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and disease outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Necrotizing fasciitis market dynamics
  • Fig. 12 Necrotizing fasciitis market: Porter's five forces analysis
  • Fig. 13 Necrotizing fasciitis market: PESTLE analysis
  • Fig. 14 Type market, 2021 - 2033 (USD Million)
  • Fig. 15 Type I (Polymicrobial) market, 2021 - 2033 (USD Million)
  • Fig. 16 Type II (Monomicrobial) market, 2021 - 2033 (USD Million)
  • Fig. 17 Type III (Gas gangrene / clostridial myonecrosis) market, 2021 - 2033 (USD Million)
  • Fig. 18 Treatment market, 2021 - 2033 (USD Million)
  • Fig. 19 Empiric broad-spectrum antibacterials market, 2021 - 2033 (USD Million)
  • Fig. 20 MRSA-coverage add-ons market, 2021 - 2033 (USD Million)
  • Fig. 21 Pathogen-targeted antibacterial regimens market, 2021 - 2033 (USD Million)
  • Fig. 22 Antifungals for necrotizing fungal infections market, 2021 - 2033 (USD Million)
  • Fig. 23 Immunotherapies market, 2021 - 2033 (USD Million)
  • Fig. 24 Distribution channel market, 2021 - 2033 (USD Million)
  • Fig. 25 Hospital pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 26 Retail pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 27 Online pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 28 Necrotizing fasciitis market revenue, by region
  • Fig. 29 Regional marketplace: Key takeaways
  • Fig. 30 North America necrotizing fasciitis market, 2021 - 2033 (USD Million)
  • Fig. 31 U.S. country dynamics
  • Fig. 32 U.S. necrotizing fasciitis market, 2021 - 2033 (USD Million)
  • Fig. 33 Canada country dynamics
  • Fig. 34 Canada necrotizing fasciitis market, 2021 - 2033 (USD Million)
  • Fig. 35 Mexico country dynamics
  • Fig. 36 Mexico necrotizing fasciitis market, 2021 - 2033 (USD Million)
  • Fig. 37 Europe necrotizing fasciitis market, 2021 - 2033 (USD Million)
  • Fig. 38 UK country dynamics
  • Fig. 39 UK necrotizing fasciitis market, 2021 - 2033 (USD Million)
  • Fig. 40 Germany country dynamics
  • Fig. 41 Germany necrotizing fasciitis market, 2021 - 2033 (USD Million)
  • Fig. 42 France country dynamics
  • Fig. 43 France necrotizing fasciitis market, 2021 - 2033 (USD Million)
  • Fig. 44 Italy country dynamics
  • Fig. 45 Italy necrotizing fasciitis market, 2021 - 2033 (USD Million)
  • Fig. 46 Spain country dynamics
  • Fig. 47 Spain necrotizing fasciitis market, 2021 - 2033 (USD Million)
  • Fig. 48 Denmark country dynamics
  • Fig. 49 Denmark necrotizing fasciitis market, 2021 - 2033 (USD Million)
  • Fig. 50 Sweden country dynamics
  • Fig. 51 Sweden necrotizing fasciitis market, 2021 - 2033 (USD Million)
  • Fig. 52 Asia Pacific Necrotizing fasciitis market, 2021 - 2033 (USD Million)
  • Fig. 53 China country dynamics
  • Fig. 54 China necrotizing fasciitis market, 2021 - 2033 (USD Million)
  • Fig. 55 Japan country dynamics
  • Fig. 56 Japan necrotizing fasciitis market, 2021 - 2033 (USD Million)
  • Fig. 57 India country dynamics
  • Fig. 58 India necrotizing fasciitis market, 2021 - 2033 (USD Million)
  • Fig. 59 Australia country dynamics
  • Fig. 60 Australia necrotizing fasciitis market, 2021 - 2033 (USD Million)
  • Fig. 61 South Korea country dynamics
  • Fig. 62 South Korea necrotizing fasciitis market, 2021 - 2033 (USD Million)
  • Fig. 63 Thailand country dynamics
  • Fig. 64 Thailand necrotizing fasciitis market, 2021 - 2033 (USD Million)
  • Fig. 65 Latin America Necrotizing fasciitis market, 2021 - 2033 (USD Million)
  • Fig. 66 Brazil country dynamics
  • Fig. 67 Brazil necrotizing fasciitis market, 2021 - 2033 (USD Million)
  • Fig. 68 Argentina country dynamics
  • Fig. 69 Argentina necrotizing fasciitis market, 2021 - 2033 (USD Million)
  • Fig. 70 MEA Necrotizing fasciitis market, 2021 - 2033 (USD Million)
  • Fig. 71 South Africa country dynamics
  • Fig. 72 South Africa necrotizing fasciitis market, 2021 - 2033 (USD Million)
  • Fig. 73 Saudi Arabia country dynamics
  • Fig. 74 Saudi Arabia necrotizing fasciitis market, 2021 - 2033 (USD Million)
  • Fig. 75 UAE country dynamics
  • Fig. 76 UAE necrotizing fasciitis market, 2021 - 2033 (USD Million)
  • Fig. 77 Kuwait country dynamics
  • Fig. 78 Kuwait necrotizing fasciitis market, 2021 - 2033 (USD Million)
  • Fig. 79 Company categorization
  • Fig. 80 Company market position analysis
  • Fig. 81 Strategic framework